Skip to main content

Unable to load price data. Sorry.


PDL BioPharma, Inc. (NASDAQ:PDLI.DL)

CAPS Rating: No stars

A biopharmaceutical company focused on discovering, developing and commercializing innovative therapies for severe or life-threatening illnesses.

Unable to load market data for this Ticker. Sorry.



This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

0 Outperform
0 Underperform

All-Star Players

0 Outperform
0 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:PDLI.DL Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

LarkinSoft (99.52)
Submitted October 29, 2015

Screened result of <=15 P/E, yields between 8-20%. Then, Current Yield divided by square root of price, adjusted for P/E, LT Debt ratio, and price % above 12-month low. Pick is within top 15 of resulting list. Premise: stock may or may not grow, but… More

mooandjeff (99.88)
Submitted September 02, 2016

In the 2nd Quarter 2016 their year over year net quarterly income fell from 78 million to 4 million, due to the loss of all income from the expired royalty agreement on all of their Queen et al patents in their contract with Genetech. Out of that 4… More



  • Sector:
  • Industry:
  • Tags:

Recent Community Commentary

Read the most recent pitches from players about PDLI.DL.

No one has written a Pitch for PDLI.DL stock yet. Tell us why you think PDLI.DL will outperform or underperform against the market.


Find the members with the highest scoring picks in PDLI.DL.

No players have picked PDLI.DL yet. Tell us why you think PDLI.DL will outperform or underperform against the market.

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for PDLI.DL.